The lancet oncology
The most recent articles from:
Lancet Oncol.
-
The lancet oncology · May 2017
Randomized Controlled Trial Multicenter Study Comparative StudyIpilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
A phase 2 trial suggested increased overall survival and increased incidence of treatment-related grade 3-4 adverse events with ipilimumab 10 mg/kg compared with ipilimumab 3 mg/kg in patients with advanced melanoma. We report a phase 3 trial comparing the benefit-risk profile of ipilimumab 10 mg/kg versus 3 mg/kg. ⋯ Bristol-Myers Squibb.